Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidate.

about

Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidate.

Item

http://www.wikidata.org/entity/Q53119150

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Activity-based exposure compar ...... ly metabolized drug candidate.

@en

Activity-based exposure compar ...... ly metabolized drug candidate.

@nl

type

Item

label

Activity-based exposure compar ...... ly metabolized drug candidate.

@en

Activity-based exposure compar ...... ly metabolized drug candidate.

@nl

prefLabel

Activity-based exposure compar ...... ly metabolized drug candidate.

@en

Activity-based exposure compar ...... ly metabolized drug candidate.

@nl

P1476

Activity-based exposure compar ...... ly metabolized drug candidate.

@en

P2093

Anna Akrami

http://www.w3.org/2001/XMLSchema#string

Dean Hickman

http://www.w3.org/2001/XMLSchema#string

Gary L Skiles

http://www.w3.org/2001/XMLSchema#string

J Greg Slatter

http://www.w3.org/2001/XMLSchema#string

Maurice G Emery

http://www.w3.org/2001/XMLSchema#string

Molly R Deane

http://www.w3.org/2001/XMLSchema#string

Raju Subramanian

http://www.w3.org/2001/XMLSchema#string

Xiaochun Zhu

http://www.w3.org/2001/XMLSchema#string

Xiping Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis.

Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data.

High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-of-flight system as a 'first-line' approach for metabolite identification studies.

Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.

11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.

Synthesis and Evaluation of the Metabolites of AMG 221, a Clinical Candidate for the Treatment of Type 2 Diabetes.

Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor.

Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).

Blockade of glucocorticoid excess at the tissue level: inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes.

Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.

P304

617-627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/00498254.2012.747711

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233938352

http://www.w3.org/2001/XMLSchema#string

P698

23244593

http://www.w3.org/2001/XMLSchema#string